Rosuvastatin, Crestor Side Effects & Dosage of Statins - MedicineNet Hypertrlyceridemia, hyperlipidemia, mixed dyslipidemia, slowing progression of atherosclerosis, primary dysbetalipoproteinemia 10-20 mg PO q Day initially; may titrate; not to exceed 40 mg/day Dosage range: 5-40 mg/day Homozygous familial hypercholesterolemia: Initiate with 20 mg PO q Day; may titrate; not to exceed 40 mg/day Primary prevention of cardiovascular disease in individuals with no cliniy evident heart disease but who are at risk because of combined effect of risk factors listed below Approval based on JUPITER trial (Justification for the Use of statins in Prevention: an Intervention Trial Evaluation Rosuvastatin) Initial: 10-20 mg PO q Day Dosage range 5-40 mg/day Patients of Asian descent: Initiate with 5 mg/day Coadministration with other lipid-lowering therapy: Consider dose reduction if combined with niacin or fenofibrate, because of increased risk for skeletal muscle effects Coadministration with cyclosporine: Not to exceed 5 mg/day Coadministration with gemfibrozil: Avoid if possible; if used together, do not exceed 10 mg/day Coadministration with ritonavir, lopinavir/ritonavir, or atazanavir/ritonavir: Not to exceed 10 mg/day Indicated to reduce LDL-C, Total-C, non HDL-C and Apo B in children and adolescents aged 7 to 17 yr with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (eg, LDL apheresis) Arthralgia (10%) Diabetes mellitus, new onset (3%) Pharyngitis (9%) Headache (6%) Asthenia (up to 5%) Dizziness (4%) CPK increased (3%) Nausea (3%) Abdominal pain (2%) ALT increased (2%) Constipation (2%) Flulike illness (2%) UTI (2%) Nonserious and reversible cognitive side effects may occur Increased blood sugar and glycosylated hemoglobin (Hb A1c) levels reported with statin intake; in some instances these increases may exceed the threshold for the diagnosis of diabetes mellitus Chronic liver disease Measure liver enzymes before initiating and if sns or symptoms of liver injury occur Consider lower initial dose (5 mg q Day) in patients with risk of myopathy Increased risk of rhabdomyolysis, especially at hhest approved dose of 40 mg/day; reserve hhest dose only for patients who fail to achieve desired cholesterol level at 20 mg/day Use 5 mg/day starting dose in people of Asian ancestry, who may build up hher drug levels and be at hher risk of myopathy Rare reports of immune-mediated necrotizing myopathy (IMNM), characterized by increased serum creatine kinase that persists despite discontinuing statin Discontinue if CK levels are markedly elevated Contraindicated Because HMG-Co A reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologiy active substances derived from cholesterol (eg, cell membranes), rosuvastatin may cause fetal harm when administered to pregnant women Contraindicated Limited data indicate that rosuvastatin is present in human milk; because statins have the potential for serious adverse reactions in nursing infants, women who require rosuvastatin treatment should not breastfeed their infants Hepatic influx and efflux transporters (single-nucleotide polymorphisms [SNPs] within the solute carrier organic anion transporter 1B1 (SLCO1B1) gene, encoding the organic anion transporter polypeptide 1B1 (OATP1B1) influx transporter) SLCO1B1 (OATP1B1) CC genotype snificantly increases AUCs of parent drug and metabolites compared with the CT or TT genotypes This polymorphism is proposed to reduced transport into the liver, the main site of statin metabolism and elimination, resulting in elevated plasma concentrations SLCO1B1 polymorphism is thought to have a lesser effect on the more hydrophilic statins (eg, rosuvastatin, fluvastatin) compared with those that are more lipophilic (eg, atorvastatin, pravastatin, simvastatin) Other genetic polymorphisms of elimination (eg, CYP450, P-glycoprotein) for each individual drug must also be considered, to explain variability for statin clearance among patients that exhibit SCLO1B1 polymorphism SLCO1B1 CC genotype is most common in Caucasians and Asians (15%); decrease dose by 50% in people of Asian descent Risk of myopathy is 2.6- to 4.3-fold hher if the C allele is present and 16.9-fold hher in CC homozygotes than in TT homozygotes The above information is provided for general informational and educational purposes only. Information on the drug rosuvastatin Crestor prescribed for. This effect depends on the dose and occurs more often at the 40 mg dose.
The Truth About Crestor Is Crestor Really Dangerous? - Mercola Individual plans may vary and formulary information changes. Statins are the hy touted drugs for reducing cholesterol. In one study, 5 mg of Crestor reduced LDL-C as much as 71 percent in subjects.13 This is. percentage reduction seen with simvastatin Zocor 20 and 40 mg.14".
CRESTOR 20 Pill - Crestor 20 mg - PRESCRIPTION: Yes GENERIC AVAILABLE: No USES: Rosuvastatin is used for the reduction of blood total cholesterol, HDL cholesterol and trlyceride levels, and to increase HDL cholesterol levels. Pill imprint CRESTOR 20 has been identified as Crestor 20 mg. Crestor is used in the treatment of hh cholesterol; atherosclerosis; hh cholesterol.
Crestor 20 mg drug:
Rating: 95 / 100
Overall: 89 Rates